p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry
1996

p53 Protein as a Prognostic Indicator in Breast Cancer

Sample size: 245 publication Evidence: moderate

Author Information

Author(s): GM Horne, JJ Anderson, DG Tiniakos, GG McIntosh, MD Thomas, B Angus, JA Henry, TWJ Lennard, CHW Horne

Primary Institution: Royal Victoria Infirmary, University of Newcastle upon Tyne

Hypothesis

The study aims to assess the expression of the p53 gene in breast carcinomas and its relation to tumor variables and patient outcomes.

Conclusion

The study found that p53 protein expression is significantly correlated with tumor grade and can serve as a prognostic indicator in breast cancer.

Supporting Evidence

  • Immunodetection of p53 varied between 37.6% and 46.6% depending on the antibody used.
  • Antibody PAb 1801 showed the strongest correlation with prognosis.
  • Positive p53 expression was associated with poorer overall survival.
  • Immunostaining for p53 correlated positively with higher tumor grade.

Takeaway

This study looked at a protein called p53 in breast cancer to see if it can help predict how well patients will do. They found that higher levels of this protein often mean worse outcomes.

Methodology

The study used immunohistochemistry to analyze p53 expression in breast carcinoma tissues from 245 patients.

Limitations

The study's findings may be limited by the small subgroup of patients assessed for response to endocrine therapy.

Participant Demographics

The study included 245 female patients with a mean age of 57.02 years.

Statistical Information

P-Value

P = 0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication